Genezen is a technical and quality-focused CDMO dedicated to advancing gene and cell therapies by providing viral vector services and manufacturing solutions. self-described.

Genezen

Genezen | 5,517 followers on LinkedIn. Accelerating the Pace of Cell Therapy CMC and Clinical Development | Founded in Indianapolis in 2014, Genezen is focused on supporting the demands of the current and future gene and cell therapy manufacturing market worldwide— making viral vector production accessible to both early-stage, growth-oriented companies and established industry leaders. Genezen offers early-phase process development, GMP lentiviral vector production, retroviral vector production, and analytical testing services, building on the company&#39;s expansive knowledge and experience in the industry and working with the nation&#39;s leading institutions. For more information, or to learn more about services offered in Genezen&#39;s new cGMP facility, please visit our website: www.genezen.com

Director of Program Management at Genezen

Gina Di Sanzo

Associate Director, Quality Control Analytical/Bioassay / Genezen

Kenya Prince Cohane

Susan D'Costa

EVP, Commercial Operations

Dave Wilhite

🌟 SURVEY RESULTS 🌟 In July 2024, we conducted a survey among top executives at biopharmaceutical companies and payor organizations to uncover how their strategies for negotiating reimbursement are shaping the development and commercialization of cell and gene therapies. Click below to see the results! #cdmo #genetherapy #cellandgenetherapy #viralvectors #pharma #biotech #payor #reimbursement #healthcare

🌟 PANEL ALERT 🌟 Pratima Cherukuri , Chief Scientific Officer for Genezen , will present on a panel entitled The Importance of Diagnostic Development in Cell and Gene Therapy Product Development on Wednesday, November 13th at the Advanced Therapies 2024 meeting in Philadelphia. #viralvectors #CDMO #celltherapy #genetherapy #cellandgenetherapy #pharma #biotech

We're excited to welcome Pam Stetkiewicz and Stuart Auerbach to our Board of Directors! With their extensive expertise in manufacturing and drug development, they will play a pivotal role in advancing Genezen as a best-in-class viral vector CDMO. https://lnkd.in/gx7J8AUd #CDMO #viralvectors #celltherapy #genetherapy #cellandgenetherapy

📣 NEW BLOG 📣 "Due to their therapeutic potential, the production of lentiviral vectors must meet the highest reliability and quality standards to ensure safety and efficacy. Reliable lentiviral vector production services are crucial for advancing gene therapy applications and clinical research." We stand at the forefront of lentiviral vector production, combining quality and precision to provide high-performing viral vectors. Learn more about our lentivirus production services: https://lnkd.in/e55bxur8 #CDMO #viralvectors #celltherapy #genetherapy #cellandgenetherapy #pharma #biotech

🗓️ SCHEDULE A CHAT 📅 Our team will be in Philly in just a couple of weeks for Advanced Therapies USA 2024. We would love to talk with you about current and upcoming projects, whether it's a la carte assistance or concept to commercial. Reach out directly to Pratima Cherukuri , Megan Hardy , and Achyuta Teella or by clicking here: https://lnkd.in/ej5uSuAD #viralvectors #CDMO #celltherapy #genetherapy #cellandgenetherapy #pharma #biotech #

🌟 PRESENTATION ALERT 🌟 Emily Carney , Senior Manager of Site Project Management, will present alongside Nicole Woon from Microsoft at the Society of Women Engineers annual conference in Chicago today. Emily has been very involved in this organization throughout her career- currently serving on the editorial board, contributing articles in its magazine, and participating as a mentor. We are proud of Emily and her service to this organization of 50k members worldwide supporting women in engineering and technology. #togetherwerise #we24 #engineering #womenengineers #viralvectors #cdmo #celltherapy #genetherapy #cellandgenetherapy #pharma #biotech

🕰️ HAPPENING NOW 🕰️ Don't miss your chance to talk with Zuelay E. Rosario, PhD about our viral vector manufacturing capabilities! Message her here on LinkedIn or via our website to set a time: https://lnkd.in/ej5uSuAD #viralvectors #cdmo #celltherapy #genetherapy #cellandgenetherapy #pharma #biotech

🏛️ ROME BOUND 🏛️ Zuelay E. Rosario, PhD will attend the European Society of Gene and Cell Therapy in Rome next week. Set some time to chat with her while you're there! https://lnkd.in/ej5uSuAD #viralvectors #cdmo #celltherapy #genetherapy #cellandgenetherapy #pharma #biotech

🤝 GENEZEN CARES 🤝 Arturo Blanquera, senior manager of automation engineering, and his wife Shannan are currently in North Carolina delivering the thousands of pounds of aid they collected for Hurricane Helene relief. Arturo coordinated this mission of mercy through the local The American Legion . We were honored to serve as a collection point and support recovery efforts. We believe in the whole person here at Genezen. To learn more about our team, click here: https://lnkd.in/emVGYgWR . #viralvectors #CDMO #celltherapy #genetherapy #cellandgenetherapy #biotech #pharma #hurricanerelief #hurricanehelene #northcarolina

🎬 THAT'S A WRAP 🎬 Pratima Cherukuri had a marvelous presentation about our capabilities to round out our presence at Alliance for Regenerative Medicine 's Meeting on the Mesa. Did you miss the presentation or your chance to talk with us? Don't worry! You can reach us right here on our website: https://lnkd.in/ej5uSuAD . Your next chance to catch us in person is coming up in Rome at ESGCT from October 22-25th! #cdmo #viralvectors #celltherapy #genetherapy #cellandgenetherapy #biotech #pharma #CGMesa24

Metric
Company Name	Genezen
Symbol
MSH ID	COM:GENEZEN
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage	Venture Round
Employee Count
Website	genezen.com
LinkedIn	genezen-laboratories
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	4.18K
Web Traffic Growth	-0.81
Valuation
Raised Capital	18.50M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

GENE

COM:GENEZEN

Genezen

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue